Physicians' Academy for Cardiovascular Education

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

Time to previous ACS event has no effect on efficacy of colchicine

5' education - Oct. 14, 2021 - Tjerk Opstal, MD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD

RAASi as a fundamental pillar in HF

10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD

Combination therapy with PCSK9 mAbs in post-MI patients

10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD

Implementation of salt substitution strategies

3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Why focus on Lp(a)?

10' education - Sep. 13, 2021 - Prof. Naveed Sattar, MD, PhD

Surgery vs. stenting with asymptomatic critical carotid artery stenosis

5' education - Sep. 7, 2021 - Prof. Freek Verheugt, MD, PhD

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD

Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD

5' education - Aug. 31, 2021 - Prof. Bertram Pitt, MD

Switching to a salt substitute reduces risk of stroke, CV events and death

5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD

Moving the field of medicine and science is a collective exercise

3' education - Aug. 29, 2021 - Prof. Stephan Achenbach, MD, president ESC

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD
It is relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.

It is relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.

Time to previous ACS event has no effect on efficacy of colchicine

5' education - Oct. 14, 2021 - Tjerk Opstal, MD
Trials with colchicine included different CVD patients; post-MI or with chronic coronary disease. Tjerk Opstal and colleagues investigated whether the efficacy of colchicine was dependent of the time to previous ACS event.

Trials with colchicine included different CVD patients; post-MI or with chronic coronary disease. Tjerk Opstal and colleagues investigated whether the efficacy of colchicine was dependent of the time to previous ACS event.

Acute arterial events reduced by PCSK9 inhibitor across all vascular territories

Literature - Oct. 14, 2021 - Oyama K, et al. - Eur Heart J 2021

Treatment with the PCSK9 inhibitor evolocumab in high CV risk patients reduced the risk of acute arterial events across all vascular territories, as shown in a post hoc analysis of FOURIER.

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD
Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.

RAASi as a fundamental pillar in HF

10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD
Prof. Coats discusses the dilemma when hyperkalemia occurs in HF: discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia.

Prof. Coats discusses the dilemma when hyperkalemia occurs in HF patients: discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia.

hsCRP reduced by GLP-1RA in patients with T2DM

News - Oct. 1, 2021

EASD 2021 Using data of four semaglutide trials, this exploratory analysis showed that both subcutaneous and oral semaglutide reduced high-sensitivity CRP in patients with T2DM.

Wide distribution of 10-year and lifetime CV risk in patients with diabetes

News - Oct. 1, 2021

EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD
The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?

The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?

GLP-1RAs reduce HbA1c, body weight and SBP regardless of background SGLT2i use

News - Sep. 29, 2021

EASD 2021 HbA1c, body weight and SBP were lowered by semaglutide and liraglutide, regardless of background SGLT2i therapy in diabetes patients, in a post hoc analysis of SUSTAIN 6.

Agenda